Table 1. Staphylococcus aureus strains used in this study.
| Strain | Characteristic(s) | Description | MIC(μg/ml) | References | ||
|---|---|---|---|---|---|---|
| Vm | Ox | Gm | ||||
| 3503-1 | OxrVmS, ST5-MRSA-II | Clinical isolate from hospital -acquired pneumonia (HAP) patient | 2 | 512 | 2 | This study |
| 3503V6 | OxrVmI | 3503 passaged to Vmifor 20 days | 6 | 8 | 2 | This study |
| 3503V10 | OxsVmI | 3503 passaged to Vmifor 45 days | 10 | 1 | 4 | This study |
| 4126-1 | OxrVmS, ST5-MRSA-II Same pulsotype as 3503-1 | Clinical isolate from HAP patient | 2 | 512 | ≥16 | This study |
| 4126VR10 | OxrVmi | 4126 passaged to Vmi | 10 | 128 | ≥16 | This study |
| 3347-1 | OxrVmS, ST239-MRSA-III | Clinical isolate from HAP patient | 1 | 256 | ≥16 | This study |
| 3347-2 | OxrVmi | 3347 passaged to Vmi | 10 | 16 | ≥16 | This study |
| 3564-1 | OxrVmS, ST239-MRSA-III | Clinical isolate from HAP patient | 2 | 256 | ≥16 | This study |
| 3564-2 | OxrVmi | 3564 passaged to Vmi | 8 | 8 | ≥16 | This study |
| 4180-1 | OxrVmS, untypedSSCmec | Clinical isolate from HAP patient | 2 | 512 | ≥16 | This study |
| 4180-2 | OxrVmi | 4180 passaged to Vmi | 10 | 128 | ≥16 | This study |
| N315 | OxsVms | MRSA carrying type II SCCmec, | 0.5 | 64 | ND | ref. 20 |
| mu50 | OxsVmi | Clinical VISA isolate, Japan, 1997 | 4 | 256 | ND | ref. 20 |
NOTE: Abbreviations: Ox, oxacillin; Vm, vancomycin; Gm, Gentamicin; r, resistant; s, sensitive; i, intermediate; ND, not determined.